Glenmark receives two ANDA approvals from the FDA

Glenmark has received ANDA approvals from the US FDA for two Oral Contraceptives – Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.03 mg and Levonorgestrel Tablet, 1.5 mg

id-100294534

Glenmark's products are the generic version of Yasmin Tablets of Bayer HealthCare Pharmaceuticals

Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.03 mg.

Glenmark's products are the generic version of Yasmin Tablets of Bayer HealthCare Pharmaceuticals and for Levonorgestrel Tablet, 1.5 mg, the generic version of Plan B One-Step Tablet of Teva Branded Pharmaceutical Products R&D for over-the-counter (OTC) use as recommended in the submitted labeling.

According to IMS Health sales data for the 12 month period ending January 2016, the Yasmin market1 achieved annual sales of approximately $131.7 million.

According to IMS Health sales data for the 12 month period ending January 2016, the Plan B One-Step Tablet OTC market1 achieved annual sales of approximately $45.2 million.

 

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X